eart failure (HF) is the final common stage of various heart diseases and has a significant effect on quality of life and prognosis. The heart relies almost exclusively on an aerobic oxidative substrate for the generation of ATP, which is required to maintain its contractile function. The balance between oxygen demand and supply is disturbed in many disease processes. The progression to HF is associated with a gradual decline in the activity of mitochondrial respiratory pathways, leading to diminished capacity for ATP production. 1 Cardiac metabolic alterations could be either adaptive or maladaptive. Furthermore, the specific etiology of HF may be of importance in the process. Cardiac metabolic alterations may correlate with the degree of left ventricular (LV) dysfunction, symptoms of HF, prognosis and the response to medical treatments. [1] [2] [3] For a better understanding of the pathophysiology of cardiac metabolic alterations, it is important to measure myocardial oxygen consumption (MV • O2). The clearance kinetics of 11 C-acetate, measured by positron emission tomography (PET), can be used to measure tricarboxylic acid cycle flux and thus enable noninvasive quantification of myocardial oxidative metabolism at both the global and regional levels. [2] [3] [4] [5] [6] [7] The level of myocardial oxidative metabolism with failing LV systolic function has been reported to be comparable to or lower than normal LV function. 8, 9 Dyssynchrony is a predictor of poor outcome and may be associated with heterogeneity of myocardial oxidative metabolism in patients with HF. Previous studies have only evaluated rather small populations because of limited availability, and clinical significance has not been clarified in broader populations with HF. In addition, the differences between ischemic (ICM) and idiopathic dilated cardiomyopathy (DCM) have not been fully investigated.
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Accordingly, the aims of this study were to evaluate myocardial oxidative metabolism by using 11 C-acetate PET in a cohort and to compare the oxidative alterations with clinical variables, such as symptoms of HF, left bundle branch block (LBBB) and echocardiographic parameters, in patients with ICM and DCM.
H
tients with symptomatic HF (New York Heart Association (NYHA) class ≥II) and LV systolic dysfunction (ejection fraction (EF) ≤50%) who underwent dynamic 11 C-acetate PET from May 2000 to December 2004. Etiology was considered ischemic in the presence of luminal stenosis ≥50% in any major epicardial coronary artery on coronary angiography, a history of myocardial infarction (MI) with electrocardiographic (ECG) evidence or prior coronary intervention procedure. The diagnosis of idiopathic DCM, based on the absence of significant luminal stenosis in any major epicardial coronary artery or primary valvular heart disease, was supported by endomyocardial biopsy. Patients were excluded if they had significant valvular heart disease (n=8), or hypertrophic (n=2) or secondary cardiomyopathy (n=7). Thirty-three patients with ICM (LVEF 33.1±9.5%) and 45 with idiopathic DCM (LVEF 34.5±10.9%) met the entry criteria.
Among 33 ICM patients, 8 (24%) had 1-vessel disease (VD), 12 had 2-VD (36%), and 13 had 3-VD (40%); 29 (88%) patients had a prior MI. There were more males in the ICM group (p=0.03). The prevalence of hypertension, diabetes and hyperlipidemia also tended to be higher in patients with ICM, but did not reach statistical significance. None of the ICM patients had ongoing chest pain during the PET studies. Meanwhile, a history of atrial fibrillation or ventricular arrhythmias tended to be more common in patients with DCM, but this was not significantly different (p=0.07 and 0.10, respectively). There were no differences in the severity of LV dysfunction between the ICM and DCM groups in terms of LV cavity dimensions, EF, or NYHA class. The characteristics of the patients with ICM and DCM are summarized in Table 1 .
The severity of HF was assessed by scoring functional class according to the NYHA class, echocardiography, and plasma B-type natriuretic peptide (BNP) measurements using a commercially available chemiluminescence enzyme immunoassay kit (MI02 SHIONOGI BNP, Shionogi Co, Ltd, Osaka, Japan) within 2 weeks of the PET studies. No clinical events or changes in medication occurred between these studies. A standard 12-lead ECG was recorded in all subjects. QRS duration was measured using the widest QRS complex from leads II, V1 and V6. The presence of LBBB was diagnosed on the basis of QRS duration ≥120 ms, absent Q wave and wide slurred R waves in V5 and V6, and monophasic QS or rS waves in V1 and V2. 10 As the control group, 14 healthy volunteers (12 men, aged 30±4 years) were recruited. All had a normal resting ECG, were nonsmokers and normotensive. None of them had cardiac symptoms or a history of cardiovascular disease, diabetes or hyperlipidemia. The study was approved by the Ethics Committee of Hokkaido University Hospital. Written informed consent was given by each subject.
Echocardiography
All echocardiographic examinations were performed by an experienced operator without knowledge of the clinical and PET data using a commercially available ultrasound system (3.5-MHz transducers; Sonos 5500; Hewlett-Packard, Palo Alto, CA, USA). Standard echocardiographic views of the LV were obtained, and the left atrial and ventricular dimensions and volumes were made according to standard criteria. LVEF was calculated from 2-dimensional echocardiographic images of the LV using the modified biplane Simpson's method. Left stroke volumes were measured from the LV outflow tract using pulsed Doppler measurement, and the outflow tract area was calculated assuming a circular configuration. 11 
C-Acetate PET Scan Protocol
The 1-11 C-acetate was synthesized according to the standard method. 12 Patients were studied after at least a 5-h fast. PET was performed using a whole-body scanner (ECAT/EXACT HR+; Siemens/CTI, Knoxville, TN, USA). Each patient received normal medication including -blockers. Transmission images were obtained using an external ring of 68 Ge for attenuation correction. After the 20-min transmission scan, 740 MBq of 11 C-acetate was administered intravenously for 60 s under resting conditions, and dynamic PET acquisition was performed (6×10, 4×15, 18×60 s). [13] [14] [15] Blood pressure, heart rate and ECG were monitored during the PET scans.
C-Acetate PET Image Analysis
PET data analysis was performed using an imaging analysis package (Dr. View; Asahi-Kasei, Tokyo, Japan) and special dedicated software. [13] [14] [15] [16] The images were iteratively reconstructed and resliced along the short axis. Regions of interest were defined for each of these images. The reconstructed dynamic PET images were analyzed by applying a 16-segment model according to the American Society of Echocardiography, including anterior, anteroseptal, septal, inferior, posterior, and lateral walls. Each wall was subdivided into the basal and midventricular portions, and the apical anterior, septal, inferior and lateral regions. 11, 15 Regional myocardial perfusion was based on the early myocardial uptake of 11 C-acetate, 60-180 s after administration. 16 Segments with reduced perfusion were defined as relative tracer uptake <50% of the maximum uptake. 15, 17 To verify the relevance of oxidative metabolism in areas adjacent to the perfusion defects in patients with ICM, the segments with preserved perfusion were further subdivided into "border segments" (areas around the hypoperfusion areas) and "remote segments" (normally perfused areas remote from the perfusion defects).
Regional oxidative metabolism was determined from the monoexponetial function (Kmono) fit to the linear portion of the semilogarithmic plot. The start of the curve was visually defined corresponding to when the blood-pool activity had cleared (usually 3-5 min) and the curve fitting as automated. [4] [5] [6] [13] [14] [15] 18 The modeling procedure resulted in 16-segment parametric polar maps of acetate clearance (rate constant, Kmono; given in min -1 ). Kmono values of all 16 segments of each measurement were averaged, and then the coefficient of variation (CV) of regional Kmono was derived as a measure of heterogeneity. To estimate the effect of perfusion defect on regional oxidative metabolism, ratios of mean Kmono values in segments of normal perfusion to hypoperfusion were compared on a patient basis.
Statistical Analysis
Data are expressed as mean ± standard deviation. 
Results

Oxidative Metabolism and Cardiac Function
The hemodynamic data during PET scans were not significantly different among the ICM, DCM and control groups. Of the 78 patients with ICM or DCM, there was a weak correlation between global Kmono and EF (r=0.27, p=0.016; Fig 1) . The trends were consistent in both groups but did not reach statistical difference, probably because of the small sample size (ICM: r=0.29, p=0.10; DCM: r=0.25, p=0.09). There were no correlations between Kmono and E/A or deceleration time on echocardiography. Overall, the patient group had a significantly reduced Kmono and higher CV than the control group (Kmono: 0.051±0.010 vs 0.059± 0.007 min -1 ; CV: 16.7±9.2 vs 9.1±2.7%, both p<0.05). In addition, patients with either ICM or DCM had reduced global Kmono and increased CV with reference to the controls, especially those with ICM (p=0.001). Patients with ICM tended to have a lower global Kmono than those with DCM, but not reaching statistical difference (p=0.16). The results are shown in Table 2 .
Analysis of Myocardial Oxidative Metabolism and Perfusion
Regional perfusion defects of the early uptake of acetate PET were seen in 31 of the 33 patients with ICM. Regional Kmono values in the hypoperfused, border and remote areas are shown in Table 3 . The Kmono values were significantly lower in the border areas than in the remote areas (p<0.05, respectively).
On the other hand, a regional perfusion defect was seen in only 6 of the 45 patients with DCM. The global Kmono values were similar between patients with or without perfusion defects; segmental Kmono values were significantly lower in the hypoperfused areas (0.044±0.012 min -1 range 0.030-0.079) than in the non-hypoperfused areas (0.054± 0.012 min -1 , range 0.021-0.068; p=0.007). Patients with regional perfusion defects tended to have a higher CV than those without, but not reaching significance (17.6±6.6 vs 13.1±5.6%; p=0.08).
Heterogeneous Oxidative Metabolism in DCM and LBBB
Eight DCM patients had LBBB, and regional perfusion defects were seen in 2 of them: 1 in the anterolateral segments and the other in the inferior segments. Of 37 DCM patients without LBBB, 4 had regional perfusion abnormalities. Therefore the remaining 39 patients with DCM showed normal perfusion: subjects with DCM and LBBB had a significantly higher CV and lower ratio of septal-tolateral Kmono than either those without LBBB or the controls (Table 4) . A larger LVDd and LVDs, and the presence of LBBB, were significantly correlated with higher CV (all p<0.001). By multivariate analysis, the presence of LBBB was an independent predictor of high CV in patients with DCM (Table 5) . Representative images are shown in Fig 2. 
Discussion
In the present study myocardial oxidative metabolism was reduced in patients with ICM and DCM. The regional heterogeneity of oxidative metabolism was greater in the patients with ICM than in those with DCM, mainly because of greater perfusion abnormalities in the former. Regional Kmono was lower in hypoperfused segments than in remote segments. Our data also show that regional heterogeneity may be used for characterizing ICM from DCM. However, we also demonstrated that regional heterogeneity exists in cases of DCM with LBBB, which might indicate different pathophysiologic processes and prognosis in the presence of LBBB. In our study, there was a reduction in Kmono in areas of hypoperfusion, mainly because of reduced oxidative metabolism in the infarcted and fibrotic areas. Studies of myocardial perfusion, sympathetic function and glucose metabolism by nuclear imaging have shown that patients with ICM have more advanced perfusion and metabolic abnormalities than those with DCM. [19] [20] [21] [22] Patients with ischemia and scarring are expected to have regional heterogeneity in both function and metabolism. The high prevalence of a history of MI and multivessel-disease in the present study population could explain the lower and more heterogeneous oxygen metabolism. 8, 15, 17, 23 We also found that oxidative metabolism was lower in the border segments than in remote ones with regard to hypoperfused areas. 18, 24 Hypoperfused segments could represent the core of the infarct and the neighboring segments could be partially infarcted. They might also reflect accelerated myocardial metabolism in remote regions in the process of LV remodeling.
The heart is unique among organ systems in its metabolic regulation, and the relationship between contractile function and oxidative metabolism could be complex. Our results suggest that acetate PET is a potential imaging modality for identifying clinical phenotypes and underlying pathophysiologic mechanisms. 25 We quantitatively estimated the heterogeneity of oxidative metabolism using CV values, an index that may be helpful in serial evaluation, especially for treatment response. Our data show that regional inhomogeneity exists in non-ischemic DCM with LBBB, as previously reported. 26, 27 In the present study, regional hypoperfusion was not uncommon in DCM patients, and reduced oxygen metabolism was frequently observed in these areas. Besides focal myocardial fibrosis, 22, [27] [28] [29] recent studies have suggested that perfusion and metabolism may be affected by endothelial dysfunction in DCM. [30] [31] [32] LBBB is known to impair LV mechanical function and is an important predictor of cardiac mortality in patients with HF caused by DCM. 10, 33 Previous studies found that perfusion and glucose metabolism were reduced in cases with LBBB, [34] [35] [36] [37] [38] [39] [40] [41] [42] and the extent of scarring correlates with QRS duration. 29 Our data show reduced septal Kmono values in the comparison of the lateral walls in patients with DCM and LBBB, and the presence of LBBB appeared to be independent of the heterogeneous metabolic changes. This result implies that LBBB may not always be caused by direct involvement of the conducting system, but rather by widespread myocardial fibrosis. We did not find significant oxidative differences in cases of right bundle branch block (RBBB), indicating different electrical activation abnormalities between LBBB and RBBB. 43 However, we did not quantify right ventricular oxidative metabolism, so our approach may not accurately reflect the metabolic alterations in patients with RBBB. 6 Previous reports have suggested that cardiac resynchronization therapy (CRT) can ameliorate the perfusion and metabolism alterations, as well as reversing LV remodeling, and may be beneficial to myocardial efficiency; [44] [45] [46] [47] [48] [49] however, 20-30% of patients still do not respond. 50, 51 Acetate PET could provide additional biologic information about the myocardium at both regional and global levels, which might guide decision making and monitor the therapeutic response. Recent studies have suggested that delayed enhancement (DE) on contrast-enhanced MRI represents irreversible myocardial injury. 52, 53 There is limited information about the correlation between the presence of DE on MRI and acetate PET findings. Combined assessment of oxygen metabolism and tissue composition might be incrementally beneficial for predicting functional improvement after CRT.
Study Limitations
First, aging has an impact on substrate metabolism in heart, and the controls in the present study were much younger. However, overall MV
• O2 was higher in the older subject, so the age factor would not affect the conclusions of our results. 54 CV was also significantly lower in the controls and the influence of aging on CV is unknown. The difference in global Kmono between the control and HF groups might be partly explained by the effect of -blockers. Second, we assessed resting perfusion from the initial uptake of 11 C-acetate and did not evaluate possible interference of inducible ischemia according to the extent of scarring. The border areas (>50% of the maximum uptake) could include non-transmural infarcted or stress-induced ischemic myocardium, which might affect the correct estimation of altered oxidative metabolism and perfusion in the border and remote segments. Thus compensatively increased oxidative metabolism in the remote areas compared with border areas should be interpreted cautiously. There was a higher prevalence of atrial fibrillation and ventricular arrhythmias among DCM patients in this series, which could be the result of a selection bias in a tertiary referral center. Third, validation data were not available. However, several studies have shown the usefulness and accuracy of Kmono assessed by 11 C-acetate PET. Fourth, the present data do not address the prognostic value of acetate PET imaging, because of the limited number of patients with severe HF in our study population. A future study with a large sample of patients that have severe LV dysfunction is warranted.
In conclusion, the present patients with HF had reduced and heterogeneous myocardial oxidative metabolism, especially those with ICM. In patients with DCM, the oxidative inhomogeneity was associated with the presence of LBBB. These findings contribute to a better understanding of the pathophysiology of LV dysfunction in relation to global oxidative metabolism and oxidative metabolic heterogeneity in patients with cardiomyopathy.
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